Ann Intern Med
- JOHANSEN ND, Vaduganathan M, Bhatt AS, Lee SG, et al
Clinical Outcomes With Electronic Nudges to Increase Influenza Vaccination : A
Prespecified Analysis of a Nationwide, Pragmatic, Registry-Based, Randomized
Implementation Trial.
Ann Intern Med. 2024 Mar 19. doi: 10.7326/M23-2638.
- KIM MS, Lee H, Lee SW, Kwon R, et al
Long-Term Autoimmune Inflammatory Rheumatic Outcomes of COVID-19 : A Binational
Cohort Study.
Ann Intern Med. 2024 Mar 5. doi: 10.7326/M23-1831.
- GRANWEHR BP
In mild to moderate COVID-19, VV116 safely reduced time to sustained clinical
symptom resolution.
Ann Intern Med. 2024 Mar 5. doi: 10.7326/J24-0006.
- PAULES CI, Wang J, Tomashek KM, Bonnett T, et al
A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From
Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the
Adaptive COVID-19 Treatment Trial-2.
Ann Intern Med. 2024 Feb 27. doi: 10.7326/M23-2593.
- OLFSON M, McClellan C, Zuvekas SH, Wall M, et al
Trends in Psychological Distress and Outpatient Mental Health Care of Adults
During the COVID-19 Era.
Ann Intern Med. 2024 Feb 6. doi: 10.7326/M23-2824.
Antiviral Res
- BANDYSZEWSKA M, Ambrozek-Latecka M, Hoser G, Grzanka M, et al
SARS-CoV-2 virus-like particle variants alpha and delta mimic the native viruses
in their differential inflammasome activating potential.
Antiviral Res. 2024 Mar 5:105857. doi: 10.1016/j.antiviral.2024.105857.
- NOBORI H, Baba K, Kuroda T, Baba K, et al
Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2.
Antiviral Res. 2024;224:105852.
- LI H, Sun M, Lei F, Liu J, et al
Methyl rosmarinate is an allosteric inhibitor of SARS-cov-2 3?C?L protease as a
potential candidate against SARS-cov-2 infection.
Antiviral Res. 2024 Feb 24:105841. doi: 10.1016/j.antiviral.2024.105841.
- BIGOTTI MG, Klein K, Gan ES, Anastasina M, et al
The alpha-dystroglycan N-terminus is a broad-spectrum antiviral agent against
SARS-CoV-2 and enveloped viruses.
Antiviral Res. 2024 Feb 20:105837. doi: 10.1016/j.antiviral.2024.105837.
BMC Pediatr
- JAMALI Z, Mohammadpour N, Sinaei R, Jafari M, et al
The footprint of SARS-COV-2 infection in neonatal late sepsis.
BMC Pediatr. 2024;24:184.
BMJ
- MCKEEVER V
Long covid and myalgic encephalomyelitis/chronic fatigue syndrome are overlapping
conditions.
BMJ. 2024;384:q613.
- WISE J
RSV: Paediatricians call on government to expedite infant vaccination programme.
BMJ. 2024;384:q706.
Epidemiol Infect
- PENG L, Huang X, Wang C, Xin H, et al
Comparative epidemiology of outbreaks caused by SARS-CoV-2 Delta and Omicron
variants in China.
Epidemiol Infect. 2024;152:e43.
- YAP WK, Attwell K
Medical exemptions to mandatory vaccinations: The state of play in Australia and
a pressure point to watch.
Epidemiol Infect. 2024;152:e40.
J Immunol
- KUNDURA L, Cezar R, Ballongue E, Andre S, et al
Low Percentage of Perforin-Expressing NK Cells during Severe SARS-CoV-2
Infection: Consumption Rather than Primary Deficiency.
J Immunol. 2024;212:1105-1112.
- ABE K, Beer JC, Nguyen T, Ariyapala IS, et al
Cross-Platform Comparison of Highly Sensitive Immunoassays for Inflammatory
Markers in a COVID-19 Cohort.
J Immunol. 2024;212:1244-1253.
J Infect
- LESTON M, Elson W, Ordonez-Mena JM, Kar D, et al
Disparities in COVID-19 Mortality Amongst the Immunosuppressed: A Systematic
Review and Meta-analysis for Enhanced Disease Surveillance.
J Infect. 2024 Jan 30:S0163-4453(24)00028-8. doi: 10.1016/j.jinf.2024.
- HUNG KC, Chen IW, Sun CK
Pulmonary dysfunction severity may impact optimal dexamethasone dosing in
patients with COVID-19.
J Infect. 2024 Feb 1:S0163-4453(24)00031-8. doi: 10.1016/j.jinf.2024.
- XIE L, Luo G, Yang Z, Wu WC, et al
The clinical outcome of COVID-19 is strongly associated with microbiome dynamics
in the upper respiratory tract.
J Infect. 2024 Feb 9:S0163-4453(24)00036-7. doi: 10.1016/j.jinf.2024.
- KALKERI R, Zhu M, Cloney-Clark S, Plested JS, et al
Altered IgG4 Antibody Response to Repeated mRNA versus Recombinant Protein
SARS-CoV-2 Vaccines.
J Infect. 2024 Feb 13:106119. doi: 10.1016/j.jinf.2024.106119.
- YAO Z, Zhang L, Duan Y, Tang X, et al
Molecular Insights into the Adaptive Evolution of SARS-CoV-2 Spike Protein.
J Infect. 2024 Feb 15:106121. doi: 10.1016/j.jinf.2024.106121.
- HITES M, Massonnaud CR, Jamard S, Goehringer F, et al
Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with
COVID-19 (DisCoVeRy): a phase 3, randomized, double-blind, placebo-controlled
trial.
J Infect. 2024 Feb 15:106120. doi: 10.1016/j.jinf.2024.106120.
- ZHOU J, Lan L, Ai S, Lin J, et al
People Living with HIV who have poor immune status are a key population for
SARS-CoV-2 prevention.
J Infect. 2024 Feb 15:106122. doi: 10.1016/j.jinf.2024.106122.
- LIU P, Cai J, Tian H, Li J, et al
Intra-host genetic diversity of SARS-CoV-2 Omicron variants in children.
J Infect. 2024 Feb 29:106132. doi: 10.1016/j.jinf.2024.106132.
- FATLY ZA, Betjes MGH, Dik WA, Fouchier RAM, et al
Mycophenolate mofetil hampers antibody responses to a broad range of vaccinations
in kidney transplant recipients: results from a randomized controlled study.
J Infect. 2024 Mar 1:106133. doi: 10.1016/j.jinf.2024.106133.
J Virol
- MARTINS M, Nooruzzaman M, Cunningham JL, Ye C, et al
The SARS-CoV-2 Spike is a virulence determinant and plays a major role on the
attenuated phenotype of Omicron virus in a feline model of infection.
J Virol. 2024 Feb 29:e0190223. doi: 10.1128/jvi.01902.
- VANSLAMBROUCK JM, Neil JA, Rudraraju R, Mah S, et al
Kidney organoids reveal redundancy in viral entry pathways during ACE2-dependent
SARS-CoV-2 infection.
J Virol. 2024 Feb 9:e0180223. doi: 10.1128/jvi.01802.
- NIU S, Zhao Z, Liu Z, Rong X, et al
Structural basis and analysis of hamster ACE2 binding to different SARS-CoV-2
spike RBDs.
J Virol. 2024 Feb 2:e0115723. doi: 10.1128/jvi.01157.
JAMA
- LU Y, Matuska K, Nadimpalli G, Ma Y, et al
Stroke Risk After COVID-19 Bivalent Vaccination Among US Older Adults.
JAMA. 2024;331:938-950.
- GRAETZ N, Hepburn P, Gershenson C, Porter SR, et al
Examining Excess Mortality Associated With the COVID-19 Pandemic for Renters
Threatened With Eviction.
JAMA. 2024;331:592-600.
- HARRIS E
Missed Vaccine Doses Tied to Worse COVID-19 Outcomes.
JAMA. 2024 Jan 31. doi: 10.1001/jama.2023.28340.
- RUBIN R
Paxlovid Is Effective but Underused-Here's What the Latest Research Says About
Rebound and More.
JAMA. 2024 Jan 31. doi: 10.1001/jama.2023.28254.
MMWR Morb Mortal Wkly Rep
- YOUSAF AR, Lindsey KN, Wu MJ, Shah AB, et al
Notes from the Field: Surveillance for Multisystem Inflammatory Syndrome in
Children - United States, 2023.
MMWR Morb Mortal Wkly Rep. 2024;73:225-228.
N Engl J Med
- HAVIARI S, Massonnaud CR, Dupont A
Recombinant Influenza Vaccine in Adults under 65 Years of Age.
N Engl J Med. 2024;390:1155.
- WOO EJ, Hulse AN
Recombinant Influenza Vaccine in Adults under 65 Years of Age.
N Engl J Med. 2024;390:1155-1156.
- HSIAO A, Fireman B, Klein NP
Recombinant Influenza Vaccine in Adults under 65 Years of Age. Reply.
N Engl J Med. 2024;390:1156.
PLoS Biol
- BEKDASH R, Yoshida K, Nair MS, Qiu L, et al
Developing inhibitory peptides against SARS-CoV-2 envelope protein.
PLoS Biol. 2024;22:e3002522.
PLoS Comput Biol
- JIJON S, Czuppon P, Blanquart F, Debarre F, et al
Using early detection data to estimate the date of emergence of an epidemic
outbreak.
PLoS Comput Biol. 2024;20:e1011934.
PLoS One
- SUWANBAMRUNG C, Srinam B, Promkool P, Suwannakarn W, et al
Uptake of COVID-19 vaccine among high-risk urban populations in Southern Thailand
using the COM-B model.
PLoS One. 2024;19:e0300509.
- TEFERA Y, Kumie A, Hailemariam D, Wakuma S, et al
Impact of Covid -19 incidence rate and government-initiated risk communication
measures on individual's NPI practices.
PLoS One. 2024;19:e0283294.
- LI Y, Li J, He J, Tao C, et al
AE-GPT: Using Large Language Models to extract adverse events from surveillance
reports-A use case with influenza vaccine adverse events.
PLoS One. 2024;19:e0300919.
- DEWA LH, Roberts L, Choong E, Crandell C, et al
The impact of COVID-19 on young people's mental health, wellbeing and routine
from a European perspective: A co-produced qualitative systematic review.
PLoS One. 2024;19:e0299547.
- JIMA LM, Atomsa GE, Allard JP, Nigatu YD, et al
The effect of malnutrition on adult Covid-19 patient's ICU admission and
mortality in Covid-19 isolation and treatment centers in Ethiopia: A prospective
cohort study.
PLoS One. 2024;19:e0298215.
- MONESS H, Mousa SO, Mousa SO, Adel NM, et al
Thrombophilia genetic mutations and their relation to disease severity among
patients with COVID-19.
PLoS One. 2024;19:e0296668.
- MOUSAVI R, Gu B
When local governments' stay-at-home orders meet the white house's "opening up
america again".
PLoS One. 2024;19:e0298115.
- LAGOS-ALVAREZ B, Zaldua Flores S, Figueroa-Zuniga J, Novoa-Munoz F, et al
Surveillance of the recurrence time of the effectiveness of national and
region-level quarantines of COVID-19 pandemic in Chile.
PLoS One. 2024;19:e0295368.
- MORISI D, Clolery H, Kon Kam King G, Schaub M, et al
How COVID-19 affects voting for incumbents: Evidence from local elections in
France.
PLoS One. 2024;19:e0297432.
- KOSKAN A, Larkey L, Todd M, Kim SW, et al
Protocol for a community-based digital storytelling pilot intervention to reduce
Hispanic parents' vaccine hesitancy to immunize their children against COVID-19.
PLoS One. 2024;19:e0299787.
- MAHMOUDIANI S
Prevalence and dynamics of contraceptive use by type during the COVID-19
pandemic: Evidence from Western Iran.
PLoS One. 2024;19:e0300613.
- TRZEBINSKI W, Trzebinski J
How does collectivism help deal with perceived vaccine artificiality? The case of
COVID-19 vaccination intent in European young adults.
PLoS One. 2024;19:e0300814.
- LEUNG H, Lim M, Lim WO, Lee SA, et al
Psychological well-being of healthcare workers during COVID-19 in a mental health
institution.
PLoS One. 2024;19:e0300329.
- VAN HAGEN CCE, Huiberts AJ, Mutubuki EN, de Melker HE, et al
Health-related quality of life during the COVID-19 pandemic: The impact of
restrictive measures using data from two Dutch population-based cohort studies.
PLoS One. 2024;19:e0300324.
- TSOU HH, Lee FJ, Wu SI, Fan B, et al
Suppression of the alpha, delta, and omicron variants of SARS-Cov-2 in Taiwan.
PLoS One. 2024;19:e0300303.
- CHUME FC, Freitas PAC, Schiavenin LG, Sgarioni E, et al
Glycated albumin in the detection of diabetes during COVID-19 hospitalization.
PLoS One. 2024;19:e0297952.
- STOSIC M, Plavsa D, Jovanovic V, Veljkovic M, et al
Factors associated with COVID-19 among hospitalized patients with severe acute
respiratory infections in Serbia, 2022-2023: A test negative case-control study.
PLoS One. 2024;19:e0299210.
- SAEED F, Ghalehnovi E, Saeidi M, Ali Beigi N, et al
Factors associated with suicidal ideation among medical residents in Tehran
during the COVID-19 pandemic: A multicentric cross-sectional survey.
PLoS One. 2024;19:e0300394.
- MELCHIORRE MG, Cerea S, Socci M, Lamura G, et al
The impact of the COVID-19 pandemic on frail older people ageing in place alone
in two Italian cities: Functional limitations, care arrangements and available
services.
PLoS One. 2024;19:e0298074.
- LUU MN, Imoto A, Matsuo Y, Huy NT, et al
Anxiety and its risk factors among non-Japanese residents living in Japan
undergoing COVID-19 situation: A cross-sectional survey.
PLoS One. 2024;19:e0280144.
- WOLLAST R, Schmitz M, Bigot A, Brisbois M, et al
Predicting health behaviors during the COVID-19 pandemic: A longitudinal study.
PLoS One. 2024;19:e0299868.
- MISQUITTA K, Miller BM, Malecek K, Gleason E, et al
A fluorescence viewer for rapid molecular assay readout in space and low-resource
terrestrial environments.
PLoS One. 2024;19:e0291158.
- LUVIANO-GARCIA JA, Loose-Esparza A, Hernandez-Ruiz YG, Sanz-Sanchez MA, et al
Risk factors for intubation and mortality in patients treated with high flow
nasal cannula due to COVID-19 infection. Survival Analysis Study in a Northern
Mexican Population.
PLoS One. 2024;19:e0296931.
- DE VRIES N, Maniscalco L, Matranga D, Bouman J, et al
Determinants of intention to leave among nurses and physicians in a hospital
setting during the COVID-19 pandemic: A systematic review and meta-analysis.
PLoS One. 2024;19:e0300377.
- OTTO AK, Prinsloo S, Natori A, Wagner RW, et al
Impact of COVID-19-related experiences on health-related quality of life in
cancer survivors in the United States.
PLoS One. 2024;19:e0297077.
- ARUMAE K, Realo A, Ausmees L, Allik J, et al
Self- and informant-reported personality traits and vaccination against COVID-19.
PLoS One. 2024;19:e0287413.
- KANTE DSI, Jebrane A, Boukamel A, Hakim A, et al
Morocco's population contact matrices: A crowd dynamics-based approach using
aggregated literature data.
PLoS One. 2024;19:e0296740.
- TARIQ MU, Ismail SB
Deep learning in public health: Comparative predictive models for COVID-19 case
forecasting.
PLoS One. 2024;19:e0294289.
- GIVI J, Fitzgerald MP
The first-to-test bias: Impact of testing order on assigning responsibility for
contagion.
PLoS One. 2024;19:e0297965.
- LEE KS, Go MJ, Choi YY, Kim MK, et al
Risk factors for critical COVID-19 illness during Delta- and Omicron-predominant
period in Korea; using K-COV-N cohort in the National health insurance service.
PLoS One. 2024;19:e0300306.
- AZZERI A, Mohamed NA, Wan Rosli SH, Abdul Samat MN, et al
Unravelling the link between SARS-CoV-2 mutation frequencies, patient
comorbidities, and structural dynamics.
PLoS One. 2024;19:e0291892.
Proc Natl Acad Sci U S A
- FLECKENSTEIN F, Stephan S, Hasse H
Elucidating the behavior of the SARS-CoV-2 virus surface at vapor-liquid
interfaces using molecular dynamics simulation.
Proc Natl Acad Sci U S A. 2024;121:e2317194121.
- GAO R, Xu X, Kumar P, Liu Y, et al
Tapered chiral nanoparticles as broad-spectrum thermally stable antivirals for
SARS-CoV-2 variants.
Proc Natl Acad Sci U S A. 2024;121:e2310469121.
Vaccine
- HILL-BATORSKI L, Bowen R, Bielefeldt-Ohmann H, Moser MJ, et al
Mucosal immunization with dual influenza/COVID-19 single-replication virus vector
protects hamsters from SARS-CoV-2 challenge.
Vaccine. 2024 Mar 19:S0264-410X(24)00327-X. doi: 10.1016/j.vaccine.2024.
- KRASILNIKOV I, Isaev A, Djonovic M, Ivanov A, et al
Transformative vaccination: A pentavalent shield against COVID-19 and influenza
with betulin-based adjuvant for enhanced immunity.
Vaccine. 2024 Mar 19:S0264-410X(23)01421-4. doi: 10.1016/j.vaccine.2023.
- MARINDA E, Mathentamo Q, Coulson N, Parker S, et al
Impact evaluation of a youth led intervention to increase COVID-19 vaccine uptake
in Kwazulu-Natal, South Africa.
Vaccine. 2024 Feb 28:S0264-410X(24)00211-1. doi: 10.1016/j.vaccine.2024.
- JABBAR F, Kadhim KA, Alhilfi RA, Chitheer A, et al
Intensification of integrated immunization services to recover routine
vaccination coverage and bring COVID-19 vaccine to the population of Iraq in
2022.
Vaccine. 2024 Feb 27:S0264-410X(24)00197-X. doi: 10.1016/j.vaccine.2024.
- MUNDO ORTIZ A, Nasri B
Socio-demographic determinants of COVID-19 vaccine uptake in Ontario: Exploring
differences across the Health Region model.
Vaccine. 2024 Feb 26:S0264-410X(24)00204-4. doi: 10.1016/j.vaccine.2024.
- SHETTY AN, Morgan HJ, Phuong LK, Mallard J, et al
Audiovestibular adverse events following COVID-19 vaccinations.
Vaccine. 2024 Feb 22:S0264-410X(24)00210-X. doi: 10.1016/j.vaccine.2024.
- LLOYD PC, Lufkin B, Moll K, Ogilvie RP, et al
Incidence rates of thrombosis with thrombocytopenia syndrome (TTS) among adults
in United States commercial and Medicare claims databases, 2017-2020.
Vaccine. 2024;42:2004-2010.
- XU S, Sy LS, Hong V, Farrington P, et al
Mortality risk after COVID-19 vaccination: A self-controlled case series study.
Vaccine. 2024 Feb 21:S0264-410X(24)00191-9. doi: 10.1016/j.vaccine.2024.
- SHOUKAT A, Bawden CE, Rost G, LeBlanc JJ, et al
Impact and cost-effectiveness analyses of vaccination for prevention of
respiratory syncytial virus disease among older adults in Ontario: A Canadian
Immunization Research Network (CIRN) study.
Vaccine. 2024 Feb 16:S0264-410X(24)00200-7. doi: 10.1016/j.vaccine.2024.
- LANG JC, Kura K, Garba SM, Elbasha EH, et al
Comparison of a static cohort model and dynamic transmission model for
respiratory syncytial virus intervention programs for infants in England and
Wales.
Vaccine. 2024;42:1918-1927.
- JIN F, Qiu Y, Wu Z, Wang YH, et al
Immunogenicity and safety of a SARS-CoV-2 mRNA vaccine (SYS6006) in healthy
Chinese participants: A randomized, observer-blinded, placebo-controlled phase 2
clinical trial.
Vaccine. 2024 Feb 15:S0264-410X(24)00124-5. doi: 10.1016/j.vaccine.2024.
- MZIOU E, Hchaichi A, Letaief H, Dhaouadi S, et al
Vaccine effectiveness against COVID-19: A test negative case-control study in
Tunisia, August 2021.
Vaccine. 2024 Feb 15:S0264-410X(24)00174-9. doi: 10.1016/j.vaccine.2024.
- ROCKSON ADJEI M, Longsignikuu A, Saeed Iddris I, Nang Suuri T, et al
Trend of measles-rubella vaccination coverage and impact on measles epidemiology
in the Savannah Region, Ghana; 2018-2022: A secondary data analysis.
Vaccine. 2024 Feb 15:S0264-410X(24)00170-1. doi: 10.1016/j.vaccine.2024.
- KIM HK, Park SK, Choe SA, Gwak ES, et al
Risk of SARS-CoV-2 breakthrough infection following NVX-CoV2373 and BNT162b2
vaccinations in Korean Adults: A population-based observational study.
Vaccine. 2024 Feb 15:S0264-410X(24)00168-3. doi: 10.1016/j.vaccine.2024.
- KUTER BJ, Brien K, Anderson S, Bass SB, et al
COVID-19 vaccine perspectives and uptake among university students three years
into the pandemic.
Vaccine. 2024 Feb 15:S0264-410X(24)00162-2. doi: 10.1016/j.vaccine.2024.
- BATHEJA A, Balkrishnan R
Rhode Island as a model for promoting flu vaccination in the United States.
Vaccine. 2024 Feb 14:S0264-410X(24)00161-0. doi: 10.1016/j.vaccine.2024.
- DONATO F, Pilotto A, Foca E, Tresoldi M, et al
The impact of time since SARS-Cov-2 vaccination, age, sex and comorbidities on
COVID-19 outcome in hospitalized patients with SARS-CoV-2 infection.
Vaccine. 2024 Feb 13:S0264-410X(24)00147-6. doi: 10.1016/j.vaccine.2024.
- HEARN EB, Kehinde G, Sambamoorthi U
Food insecurity and COVID-19 vaccine hesitancy among adults in the United States
(US).
Vaccine. 2024 Feb 13:S0264-410X(24)00102-6. doi: 10.1016/j.vaccine.2024.
- KLASSEN AC, Lee G, Chiang S, Murray R, et al
Did the COVID-19 experience change U.S. parents' attitudes towards HPV
vaccination? Results from a national survey.
Vaccine. 2024 Feb 14:S0264-410X(24)00142-7. doi: 10.1016/j.vaccine.2024.
- LIJESKIC O, Bauman N, Markovic M, Srbljanovic J, et al
SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose:
Homologous versus heterologous boost.
Vaccine. 2024 Feb 10:S0264-410X(24)00110-5. doi: 10.1016/j.vaccine.2024.
- BUEKENS P, Berrueta M, Ciapponi A, Bardach A, et al
Safe in pregnancy: A global living systematic review and meta-analysis of
COVID-19 vaccines in pregnancy.
Vaccine. 2024 Feb 9:S0264-410X(24)00158-0. doi: 10.1016/j.vaccine.2024.
- WADAPURKAR R, Singh S, Singh A
Leveraging the immunoinformatics approach for designing the SARS-CoV-2
omicron-specific antigenic cassette of mRNA vaccine.
Vaccine. 2024 Feb 8:S0264-410X(24)00111-7. doi: 10.1016/j.vaccine.2024.
- MAEDA M, Murata F, Fukuda H
The age-specific impact of COVID-19 vaccination on medical expenditures and
hospitalization duration after breakthrough infection: The Vaccine Effectiveness,
Networking, and Universal Safety (VENUS) Study.
Vaccine. 2024 Feb 5:S0264-410X(24)00106-3. doi: 10.1016/j.vaccine.2024.
- RIVERS P, Porter C, LeClair LB, Jeddy Z, et al
Longitudinal parental perception of COVID-19 vaccines for children in a
multi-site, cohort study.
Vaccine. 2024 Feb 2:S0264-410X(24)00010-0. doi: 10.1016/j.vaccine.2024.
- MADNI SA, Sharma AJ, Zauche LH, Waters AV, et al
CDC COVID-19 Vaccine Pregnancy Registry: Design, data collection, response rates,
and cohort description.
Vaccine. 2023 Dec 5:S0264-410X(23)01423-8. doi: 10.1016/j.vaccine.2023.
- LAVELL AHA, Schramade AE, Sikkens JJ, van der Straten K, et al
25-Hydroxyvitamin D concentrations do not affect the humoral or cellular immune
response following SARS-CoV-2 mRNA vaccinations.
Vaccine. 2023 Sep 27:S0264-410X(23)00957-X. doi: 10.1016/j.vaccine.2023.
- KIM YA, Mousavi K, Yazdi A, Zwierzyna M, et al
Computational design of mRNA vaccines.
Vaccine. 2023 Jul 20:S0264-410X(23)00836-8. doi: 10.1016/j.vaccine.2023.
Virology
- SAKA N, Nishio M, Ohta K
Human parainfluenza virus type 2 V protein inhibits mitochondrial apoptosis
pathway through two ways.
Virology. 2024;594:110053.
Virus Res
- JANSEN JM, Meineke R, Molle A, van de Sandt CE, et al
Selective pressure mediated by influenza virus M1(58-66) epitope-specific CD8(+)T
cells promotes accumulation of extra-epitopic amino acid substitutions associated
with viral resistance to these T cells.
Virus Res. 2024;343:199355.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016